Epigral Ltd Q3 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 5 Aug 2026 | Chemicals & Petrochemicals | Market Cap: ₹4.8K Cr
FY '27 expected to see good volume growth as FY '26 volumes were muted due to early/prolonged monsoon and subdued demand. Epigral is targeting consistent growth through expansion and diversification across multiple products and industries (Page 17).
From Epigral Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹1,126
Market Cap
₹4.8K Cr
P/E Ratio
17.8
How does Epigral Ltd rank in Chemicals & Petrochemicals?
Compare Epigral Ltd against every Chemicals & Petrochemicals company this quarter on revenue, margins and earnings-call signals.
Epigral Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹736 Cr, net profit ₹82 Cr.
Full financials →📊 Revenue & Sales Performance
- →FY '27 expected to see good volume growth as FY '26 volumes were muted due to early/prolonged monsoon and subdued demand.
- →Q4 FY '26 volumes likely to improve with uptick in demand from mid-November and better market conditions.
- →CPVC demand projected to grow 10-12% annually, anticipated to reach around 320,000 tonnes by FY '27 end, with long-term growth towards 500,000 tonnes by FY '30.
- →Chlorotoluene segment expected to contribute sizable revenue from FY '27 onwards, with major orders and contracts starting Q1 FY '27.
- →Epigral is commissioning expansions in CPVC and epichlorohydrin capacity; initial lower utilization expected post-commissioning but achieving optimal utilization within 1-2 years.
- →New projects and value chain extensions set to drive significant growth from FY '29 onwards.
- →Overall, management anticipates consistent growth aligned with expansion, diversification, and improving market demand.
📈 Profitability & Margins
- →Epigral is targeting consistent growth through expansion and diversification across multiple products and industries (Page 17).
- →Q4 FY26 expected to see better volume and margin recovery after Q3 challenges (Pages 12-13).
- →Margins expected to improve to around 21%-23% in Q4 and onwards (Page 13).
- →Chlorotoluene value chain plant commissioned March 2025, expected to contribute sizably to profits starting FY27 (Page 4).
- →New capacities for CPVC and epichlorohydrin doubling planned, expected to be optimally utilized within 1-2 years, supporting revenue growth (Pages 7-9).
- →Volume growth anticipated in FY27 due to recovery in demand after subdued FY26 (Page 13).
- →New projects and expanded integrated complex set to drive significant growth from FY29 onwards (Page 4).
- →Management expects improvement in overall performance and profitability from FY27 onwards onward (Pages 4, 13, 17).
🏗️ Capital Expenditure Plans
- →Capex of INR 337 crores spent; ongoing capex plans progressing as per schedule.
- →Projects to double capacity at CPVC and epichlorohydrin, and wind solar hybrid power plants on track for commissioning within announced timeline and budget.
- →Chlorotoluene value chain plant commissioned in March 2025, expected to contribute significantly to profit from FY27 onwards.
- →New projects’ capex plans are being finalized, with details expected to be announced in the coming months.
- →These investments aim to enhance integrated complex, extend value chain, and drive strong growth from FY27 onward, with significant growth expected from FY29 onward.
- →Strategy targets 70% revenue contribution from derivatives and specialty business through expansion and diversification.
💰 Fundraising & Capital Structure
- →The transcript does not mention any current or planned fundraising through debt or equity.
- →As of December 31, 2025, Epigral's net debt was INR 557 crores with a net debt to EBITDA ratio of 1x, indicating a comfortable debt position.
- →The company is focused on capex projects including capacity expansion in CPVC and epichlorohydrin and wind solar hybrid power plants, progressing on schedule within budget.
- →No explicit indication in the call regarding raising funds via equity or additional debt.
- →Management emphasizes disciplined capital efficiency and execution to fund growth internally.
- →Any new capex plans will be finalized and announced in the coming months, but there's no mention of external fundraising for these.
📋 Order Book & Pipeline
- →Chlorotoluene segment orders are currently on a quarterly basis as customers are testing and building confidence.
- →Actual deliveries are happening on a full truckload basis, not just samples.
- →Major volume orders and long-term contracts are expected to begin from FY '27 onwards.
- →The company anticipates a sizable revenue contribution from the chlorotoluene plant starting Q1 FY '27.
- →As approvals and customer contracts finalize, order visibility will improve by March.
- →The management is cautious about making firm commitments on orderbook percentages before contracts finalize.
- →The increasing volumes in chlorotoluene indicate growing acceptance, but long-term orderbook/build-up is still in progress.
Key Metrics
Frequently Asked Questions
What were Epigral Ltd Q3 FY26 results?
FY '27 expected to see good volume growth as FY '26 volumes were muted due to early/prolonged monsoon and subdued demand. Epigral is targeting consistent growth through expansion and diversification across multiple products and industries (Page 17).
What is Epigral Ltd share price analysis?
Epigral Ltd currently shows a neutral. The stock trades at a P/E of 17.8 with a market cap of ₹4,828 Cr. Investors should review the full earnings analysis for detailed insights.
Is Epigral Ltd planning capital expenditure?
Capex of INR 337 crores spent; ongoing capex plans progressing as per schedule.
Keep Epigral Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.